Cyclic Vomiting Syndrome in Adults at the National Level: Impact of Demographics, Burden of Comorbidities, Effect of Hospital Factors, and Determinants of Mortality
- PMID: 40372977
- DOI: 10.1097/MCG.0000000000002180
Cyclic Vomiting Syndrome in Adults at the National Level: Impact of Demographics, Burden of Comorbidities, Effect of Hospital Factors, and Determinants of Mortality
Abstract
Goals: The aim of this study was to assess clinical, economic, and epidemiological characteristics of hospitalized patients in the United States with cyclic vomiting syndrome (CVS).
Background: CVS is a poorly understood disorder of gut-brain interaction (DGBI) characterized by recurring episodes of intractable nausea and vomiting.
Study: The study utilized the Healthcare Cost and Utilization Project's National Inpatient Sample between 2016 and 2019. χ2 test and logistic regression were performed to compare the variables. All analyses included sample weights, strata, and clusters to account for the complex survey design.
Results: Admission rates declined from 11,055 in 2016 to 8625 in 2019. Mean age (34.7 y), females (62.5%), and racial distribution (61.8% white) remained stable. Patients were more likely to be 18 to 30 years old (37.2%) and female (62.5%). Comorbidities included anxiety/depression (38.6%) and cannabis use (35.0%). Overall, 90.4% were discharged routinely (ie, to home). Older age (P=0.002) and female gender (P<0.001) had higher length of stay (LOS) and charges. Hispanics incurred higher costs (P<0.001). Depression/anxiety comorbidity (P<0.001) and teaching hospitals (P<0.001) were associated with significantly higher LOS and cost.
Conclusions: The number of hospitalizations declined between 2016 and 2019, with the latter having 8625 hospitalizations costing over $300 million. Young females represent a larger group, African Americans were disproportionally affected, and Hispanics had the highest hospitalization costs. Anxiety and depression are primary comorbidities. The disparities identified can help clinicians identify riskier CVS patients who may become a burden on the healthcare system, stratifying them for closer monitoring with the goal of improved outcomes.
Keywords: cyclic vomiting syndrome; demographics; national costs; national trends; outcomes.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Sakakibara R. Cyclic vomiting syndrome: the nervous system has the guts. Clin Auton Res. 2018;28:167–169.
-
- Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Neurogastroenterol Motil. 2019;31:e13604.
-
- Boles RG, Adams K, Li BU. Maternal inheritance in cyclic vomiting syndrome. Am J Med Genet A. 2005;133A:71–77.
-
- Bhandari S, Jha P, Thakur A, et al. Cyclic vomiting syndrome: epidemiology, diagnosis, and treatment. Clin Auton Res. 2018;28:203–209.
-
- Bashashati M, Bradshaw HB, Johnson CT, et al. Plasma endocannabinoids and cannabimimetic fatty acid derivatives are altered in cyclic vomiting syndrome: the effects of sham feeding. J Investig Med. 2023;71:821–829.
LinkOut - more resources
Full Text Sources
